AbbVie Q3 2026 Earnings: EPS More Than Doubles Year Over Year
AbbVie posted strong third-quarter results with both GAAP and adjusted diluted EPS surging more than 100% versus the prior-year period.
AbbVie reported third-quarter 2026 financial results Friday, disclosing diluted earnings per share of $2.37 on a GAAP basis, a gain of more than 100 percent compared with the same period a year earlier. Adjusted diluted EPS came in at $3.82, also representing more than 100 percent growth year over year.
The pharmaceutical giant noted that both EPS figures were weighed down by an unfavorable impact of $0.11 per share tied to acquired in-process research and development charges and milestones expense, costs that typically reflect ongoing deal activity and pipeline investments.
Read more NatGold Digital Pulls NATG Token From MEXC After U.S. Treasury Action →
The double-digit earnings expansion underscores a significant turnaround in profitability for AbbVie, which has been navigating the post-patent landscape for its legacy blockbuster Humira while leaning on newer immunology and oncology assets to sustain revenue momentum. The inclusion of IPR&D charges signals continued investment in external innovation, a strategy the company has pursued through licensing agreements and acquisitions.
Analysts will likely scrutinize whether the underlying adjusted figure, stripped of acquisition-related costs, reflects durable operational improvement or a favorable comparison against a weak prior-year base. The more-than-100-percent growth rate, while striking, warrants examination of the year-ago baseline when assessing the sustainability of AbbVie's earnings trajectory.
Continue reading at Earnings.
